Dual MAPK inhibition (dMAPKi) as an effective therapeutic strategy for class II BRAF mutant (mt) metastatic melanoma (MM).Matthew Dankner, April A. N. Rose, Dana Vuzman et al.|Journal of Clinical Oncology|2018Cited by 0